Challenges For Bioresorbable Stents In Peripheral Arterial Disease
Executive Summary
Are bioresorbable stents for peripheral arterial disease losing their luster, even before getting to the market? Expectations for drug-eluting balloons seem to be soaring at stents’ expense.
You may also be interested in...
Vascular Interventional Devices: New Avenues For Growth
Manufacturers are finding it harder to innovate in the vascular interventional devices as market and regulatory pressures take their toll. New coronary drug-eluting stents face a difficult challenge with the high bar now set by existing devices, and there have been several recent disappointments in renal denervation, drug-coated balloons, and renal artery stenting; still there are some promising areas, with bioresorbable stents offering perhaps the best prospect among vascular therapies for future blockbuster status.
Research Briefs: Abbott Peripheral Stent Data; Biotronik MRI Pacemaker Study
Six-month data from the ESPRIT trial show that Abbott’s Esprit BVS, a peripheral stent based on the same technology as the Absorb BVS, reduces symptoms and keeps arteries open. Biotronik also announced that it has moved into the second phase of an MRI-compatibility trial of its Entovis pacemaker. More research news.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”